RxDoctor Payments Data

Melissa Mathis, PA

Physician Assistant · Gastonia, NCNPI 1972558476

Payments from drug & device makers

$9,540in general payments, 2019–2025

Across 337 payments — averaging $28.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$4K
  • Gilead$2K
  • Theratechnologies Inc.$1K
  • AbbVie$831
  • Merck$439
  • Paratek Pharmaceuticals, Inc.$402
  • plus $1K from 8 others

What the payments were for

  • Consulting fees$3,23034%
  • Food & beverage$5,96363%
  • Education$3464%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,540 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$33,169
Medicare patients
192
Services billed
2,205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala637$2,641,862
GenvoyaElviteg/Cob/Emtri/Tenof Alafen166$684,041
DovatoDolutegravir Sodium/Lamivudine162$500,995
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf64$280,487
TivicayDolutegravir Sodium83$209,624
TriumeqAbacavir/Dolutegravir/Lamivudi45$168,251
PrezcobixDarunavir/Cobicistat58$155,135
CabenuvaCabotegravir/Rilpivirine19$131,064
JulucaDolutegravir/Rilpivirine26$97,076
DalvanceDalbavancin Hcl15$75,183
OdefseyEmtricitab/Rilpiviri/Tenof Ala14$57,520
Daptomycin54$35,725
DescovyEmtricitabine/Tenofov Alafenam13$28,028
Cefepime Hcl48$11,515
Darunavir14$11,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$1,543$3,353,930816 claims
Viiv Healthcare CompanyDovato, Tivicay, Triumeq, Cabenuva, Juluca$4,105$1,107,010335 claims
Janssen Products, LPSymtuza$267$280,48764 claims
Johnson & JohnsonPrezcobix$364$155,13558 claims
AbbVieDalvance$831$75,18315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Gastonia

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →